Andrew Sinclair
Directeur/Membre du Conseil chez SOLENO THERAPEUTICS, INC.
Fortune : 10 679 $ au 30/04/2024
Profil
Andrew Sinclair is currently an Independent Director at Soleno Therapeutics, Inc. and a Managing Director at Abingworth LLP.
He is also an Independent Director at Adicet Bio, Inc., a Director at Locki Therapeutics Ltd., and a Director at Entact Bio, Inc. In addition, Dr. Sinclair is a Portfolio Manager & Partner at Abingworth Management Ltd.
He is a Member of the Institute of Chartered Accountants in England & Wales.
Previously, he served as an Independent Director at Sierra Oncology, Inc. from 2019 to 2022.
He was also a Director at HSBC Global Markets Select Funds Plc, a Director at Abingworth Bioventures VI LP from 2016 to 2020, and an Independent Non-Executive Director at Verona Pharma Plc.
Dr. Sinclair worked as a Research Analyst at Credit Suisse Securities (Europe) Ltd.
and as a Research Analyst at HSBC Bank Plc (Broker) from 2007 to 2008.
He obtained his undergraduate degree from King's College London.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ADICET BIO INC
0,01% | 09/04/2024 | 5 900 ( 0,01% ) | 10 679 $ | 30/04/2024 |
SOLENO THERAPEUTICS INC
-.--% | 26/05/2023 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Andrew Sinclair
| Sociétés | Poste | Début |
|---|---|---|
| SOLENO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 21/12/2018 |
| ADICET BIO, INC. | Directeur/Membre du Conseil | 02/03/2021 |
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Analyste en capital-investissement | 25/11/2008 |
Abingworth Management Ltd.
 Abingworth Management Ltd. Investment ManagersFinance Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01/01/2008 |
Institute of Chartered Accountants in England & Wales
 Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services The Institute of Chartered Accountants in England & Wales ensures that its members, students, and affiliates maintain the highest standards of professional competency and conduct to protect the public interest. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. With over 150,000 members, the institute provides technical information, helplines, and communities to its members. | Corporate Officer/Principal | - |
Locki Therapeutics Ltd.
 Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | Directeur/Membre du Conseil | 04/11/2021 |
Entact Bio, Inc.
 Entact Bio, Inc. BiotechnologyHealth Technology Entact Bio, Inc. is a company that focuses on creating new medicines by enhancing protein function. The company is based in Watertown, MA. The company is a team of scientists, entrepreneurs, drug creators, and problem solvers who work together to bring new medicines to patients who currently have few options. The CEO of the company is Victoria M. Richon. The founder of the company grew up in chaos and instability in an undisclosed capital city and has always been passionate and motivated to help enhance and provide medical solutions. | Directeur/Membre du Conseil | - |
Anciens postes connus de Andrew Sinclair
| Sociétés | Poste | Fin |
|---|---|---|
| SIERRA ONCOLOGY, INC. | Directeur/Membre du Conseil | 01/07/2022 |
Abingworth Bioventures VI LP
 Abingworth Bioventures VI LP Investment ManagersFinance Abingworth Bioventures VI LP invests in private and public companies located the US and Europe. The fund targets companies operating in the fields of medical devices, instrumentation, bio therapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, diagnostics and software. The fund provides financing for seed, early and late stage capital requirements with an investment size of $15 - $30 million. It seeks Majority or minority investments in the companies. | Directeur/Membre du Conseil | 01/01/2020 |
| ░░░░ ░░░░ ░░░ ░░░░░░░░ | ░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░ ░░░░░░░ ░░░░░░ ░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Andrew Sinclair
| King's College London | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| SOLENO THERAPEUTICS, INC. | Health Technology |
| VERONA PHARMA PLC | Health Technology |
| ADICET BIO, INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
| HSBC Global Markets Select Funds Plc | Miscellaneous |
Abingworth Management Ltd.
Abingworth Management Ltd. Investment ManagersFinance Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom. | Finance |
Abingworth Bioventures VI LP
Abingworth Bioventures VI LP Investment ManagersFinance Abingworth Bioventures VI LP invests in private and public companies located the US and Europe. The fund targets companies operating in the fields of medical devices, instrumentation, bio therapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, diagnostics and software. The fund provides financing for seed, early and late stage capital requirements with an investment size of $15 - $30 million. It seeks Majority or minority investments in the companies. | Finance |
Abingworth LLP
Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Finance |
Institute of Chartered Accountants in England & Wales
Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services The Institute of Chartered Accountants in England & Wales ensures that its members, students, and affiliates maintain the highest standards of professional competency and conduct to protect the public interest. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. With over 150,000 members, the institute provides technical information, helplines, and communities to its members. | Commercial Services |
Credit Suisse Securities (Europe) Ltd.
 Credit Suisse Securities (Europe) Ltd. Investment Banks/BrokersFinance Credit Suisse Securities (Europe) Ltd. (Credit Suisse Europe) is the Great Britain-based brokerage subsidiary of Credit Suisse Investment Holdings (UK), itself a subsidiary of Credit Suisse Group AG (SWX: CSGN) in Switzerland. The firm was founded in 1966 and formerly known as Credit Suisse First Boston (Europe) Ltd. Headquartered in London, Credit Suisse Europe arranges financing in international capital markets, provides financial advisory services and acts as a dealer in securities, derivatives and foreign exchange on a principal and agency basis for corporate and institutional investors. | Finance |
HSBC Bank Plc (Broker)
 HSBC Bank Plc (Broker) Investment Banks/BrokersFinance HSBC Bank Plc (Broker) (HSBC Bank-Broker) is the broker/dealer division of HSBC Bank Plc, which is owned by HSBC Holdings Plc (LON: HSBA; NYSE: HSBC) in Great Britain. Headquartered in London, HSBC Bank-Broker was founded in 1880 and offers bespoke brokerage services across every major asset class for their corporate and institutional clients. | Finance |
Locki Therapeutics Ltd.
Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | Health Technology |
Entact Bio, Inc.
Entact Bio, Inc. BiotechnologyHealth Technology Entact Bio, Inc. is a company that focuses on creating new medicines by enhancing protein function. The company is based in Watertown, MA. The company is a team of scientists, entrepreneurs, drug creators, and problem solvers who work together to bring new medicines to patients who currently have few options. The CEO of the company is Victoria M. Richon. The founder of the company grew up in chaos and instability in an undisclosed capital city and has always been passionate and motivated to help enhance and provide medical solutions. | Health Technology |
